Key result
The AHEAD score was associated with all-cause mortality and cardiovascular mortality in an Asian cohort of acute heart failure patients.
Why the study?
Does the AHEAD score predict long-term mortality in Asian patients with acute heart failure?
Cohort (n=2,143)
Does the AHEAD score predict long-term mortality in Asian patients with acute heart failure?
The AHEAD score, and a modified AHEAD-U score including uric acid, effectively predict long-term all-cause and cardiovascular mortality in Asian patients with acute heart failure regardless of ejection fraction.
Answers are grounded in this paper and cite their sources.
Supports AHEAD score for risk stratification in Asian acute HF; leaves open prospective validation before practice change.
BACKGROUND: AHEAD (A: atrial fibrillation; H: hemoglobin; E: elderly; A: abnormal renal parameters; D: diabetes mellitus) score has been related to clinical outcomes of acute heart failure. However, the prognostic value of the AHEAD score in acute heart failure patients with either reduced or preserved left ventricular ejection fraction (HFrEF and HFpEF) remain to be elucidated. METHODS AND RESULTS: The study population consisted of 2143 patients (age 77±12 years, 68% men, 38% HFrEF) hospitalized primarily for acute heart failure with a median follow-up of 23.75 months. The performance of the AHEAD score (atrial fibrillation, hemoglobin <13 mg/dL for men and 12 mg/dL for women, age >70 years, creatinine >130 μmol/L, and diabetes mellitus) was evaluated by Cox's regression analysis for predicting cardiovascular and all-cause mortality. The mean AHEAD scores were 2.7±1.2 in the total study population, 2.6±1.3 in the HFrEF group, and 2.7±1.1 in the HFpEF group. After accounting for sex, sodium, uric acid, and medications, the AHEAD score remained significantly associated with all-cause and cardiovascular mortality (hazard ratio and 95% CI: 1.49, 1.38-1.60 and 1.48, 1.33-1.64), respectively. The associations of AHEAD score with mortality remained significant in the subgroups of HFrEF (1.63, 1.47-1.82) and HFpEF (1.34, 1.22-1.48). Moreover, when we calculated a new AHEAD-U score by considering uric acid (>8.6 mg/dL) in addition to the AHEAD score, the net reclassification was improved by 19.7% and 20.1% for predicting all-cause and cardiovascular mortality, respectively. CONCLUSIONS: The AHEAD score was useful in predicting long-term mortality in the Asian acute heart failure cohort with either HFrEF or HFpEF. The new AHEAD-U score may further improve risk stratification.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2017) conducted a cohort in Acute heart failure (n=2,143). AHEAD score was evaluated on all-cause mortality (HR 1.49, 95% CI 1.38-1.60). The AHEAD score was associated with all-cause mortality and cardiovascular mortality in an Asian cohort of acute heart failure patients.
Synapse has enriched 10 related papers. Consider them for comparative context: